NBRV News and Press, Nabriva Therapeutics plc From 04/11/19

DUBLIN, Ireland, April 11, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that it will present data at the 29 th European Congress of C...

Gainers: Nordic American Offshore (NYSE: NAO ) +33%.  Melinta Therapeutics (NASDAQ: MLNT ) +23% . New Age Beverages (NASDAQ: NBEV ) +21% . Celldex Therapeutics (NASDAQ: CLDX ) +18% . Reliv International (NASDAQ: RELV ) +18% . Niu Technologies (NASDAQ: NIU ) +18% . Laredo Petrol...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees a heavy dose of healthcare companies presenting at investor con...

DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 02, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that Chief Executive Officer Ted Schr...

DUBLIN, Ireland, April 01, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an...

Moleculin Biotech (NASDAQ: MBRX )  -25%  on announcing equity offering. More news on: Moleculin Biotech, Inc., DropCar, Inc., Fibrocell Science, Inc., Stocks on the move, Read more ...

Nabriva Therapeutics ( NBRV ) has two separate drugs in regulatory stages, with lefamulin (IV/oral) targeting community-acquired bacterial pneumonia ((CABP)) and Contepo ((IV)) targeting cUTI or complicated urinary tract infection. Contepo has a PDUFA on April 30, 2019, and lefamulin on August...

In October 2018, Paratek Pharmaceuticals ( PRTK ) received FDA approvals for its two main products - SEYSARA and NUZYRA. The company also entered into an exclusive licensing agreement with Almirall ( LBTSF ) for the development and commercialization rights of SEYSARA, which was launched in the...

Nabriva Therapeutics (NASDAQ: NBRV ): FY GAAP EPS of -$2.26. More news on: Nabriva Therapeutics plc, Earnings news and commentary, Healthcare stocks news, , Read more ...